Antifungals Market Forecast Through 2030 With Insights On Market Patterns And Developments

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Antifungals Market Grow Between 2026 And 2030?

The antifungals market size has experienced significant growth in recent years. It is projected to expand from $29.6 billion in 2025 to $31.98 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the historic period stems from factors such as an increase in hospital-acquired infections, the widespread use of azoles, a rising immunosuppressed population, established antifungal therapies, and the global burden of mycoses.

The antifungals market is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $44.96 billion, demonstrating a compound annual growth rate (CAGR) of 8.9%. This projected growth is driven by several factors, including an increase in systemic fungal infections, worries about antifungal resistance, a need for safer treatment options, the expansion of hospital services, and improved diagnosis rates. Key trends expected during this period involve a rising occurrence of fungal infections, an increasing call for broad-spectrum antifungal agents, the proliferation of topical antifungal remedies, their greater application in immunocompromised individuals, and the creation of new classes of antifungal drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Primary Drivers Are Shaping The Antifungals Market?

The escalating occurrence of fungal infections is anticipated to stimulate the expansion of the antifungals market in the future. Fungal infections are illnesses resulting from fungi invading and growing within or on the body, impacting various areas such as the skin, nails, lungs, and mucous membranes. The increasing frequency of fungal infections can be attributed to climate change, which fosters conditions suitable for fungi to spread and adapt to elevated temperatures, thereby heightening human exposure and infection risks. Antifungals are vital in treating fungal diseases by hindering fungal growth and reproduction, either by damaging their cell wall or membrane, obstructing critical enzymatic processes, or impeding their ability to synthesize essential components, consequently diminishing fungal load, alleviating symptoms, and preventing the spread of infection within the body. For example, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast saw a 4% increase in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Hence, the growing incidence of fungal infections is a key factor propelling the antifungals market. The expansion of healthcare infrastructure is expected to propel the antifungals market forward. Healthcare infrastructure encompasses the physical and organizational structures, facilities, and systems that facilitate the provision of healthcare services. This rise in healthcare infrastructure is primarily driven by increased government support and investments, delivered through various policies and incentives that encourage the development of healthcare facilities. This infrastructure comprises the necessary facilities, systems, and resources required for delivering effective healthcare services for the management of fungal infections. For instance, in May 2024, Baker McKenzie, an Australia based law firm, reported that the Australian government allocated $1.82 billion (AUD 2.8 billion) to strengthen Medicare, building upon the $3.95 billion (AUD 6.1 billion) Medicare investment from the 2023-24 Federal Budget, and an additional USD 91.48million (AUD 141.1 million) for medical research and services for individuals living with chronic conditions such as bowel and skin cancer, diabetes, and dementia. Therefore, the expanding healthcare infrastructure is a significant driver for the growth of the antifungals market.

Which Segment Categories Are Included In The Antifungals Market Segment Analysis?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Trends Are Affecting The Direction Of The Antifungals Market?

Major companies in the antifungals market are concentrating on product innovation and new formulations, such as long-acting echinocandin therapies, to boost patient adherence, decrease dosing frequency, and address outstanding clinical requirements for invasive fungal infections. By increasing their half-life and modifying pharmacokinetics, these next-generation antifungals ensure effective fungal suppression with more convenient administration schedules. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, alongside Melinta Therapeutics (U.S.), announced FDA approval for REZZAYO (rezafungin for injection) for managing candidemia and invasive candidiasis. Rezafungin functions as a once-weekly echinocandin, proving non-inferior efficacy compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while maintaining a comparable safety profile. The extended dosing capability of REZZAYO bridges a significant gap in antifungal therapy, improving treatment continuity and lessening the hospital burden in acute-care settings.

Who Are The Active Companies Shaping The Antifungals Market?

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Get The Full Antifungals Market Report:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Holds The Highest Market Share In The Antifungals Market?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antifungals Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Browse Through More Reports Similar to the Global Antifungals Market 2026, By The Business Research Company

Antifungals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Fungicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/fungicides-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795